The results showed that PathoQuest’s proprietary NGS approach is an effective, more robust replacement to in vivo adventitious virus testing of cell substrates used in the production of biologics, like monoclonal antibodies, vaccines, and cell, and gene therapies. On Sept. 6, 2023, Charles River Laboratories International and PathoQuest announced
The agreement states that Orbit will implement its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumors. Orano Med and Orbit Discovery announced on Sept. 11, 2023, that they have entered a collaboration to discover specific peptide receptor radionuclide therapies against cancer cells and
The new policy will require trading partners to supply, accept, and manage all documentation of products and ownership of prescription drugs electronically. FDA announced on Aug 30, 2023, that it is creating two compliance policy guidances initiating a year-long stabilization period for those in the pharmaceutical supply chain that need
Optibrium announced on Aug. 31, 2023 the acquisition of BioPharmics to further expand the 3D drug design and modelling offering and to focus on research and development and application science. Optibrium announced on Aug. 31, 2023 the acquisition of BioPharmics to further expand the 3D drug design and modelling offering
Illumina’s new solutions center in Bengaluru, India, will expand access to genomics in the country. The opening of a new solutions center in Bengaluru, India, by Illumina, a US-based company specializing in DNA sequencing and array-based technologies, in August 2023 not only expands Illumina’s capabilities in genomics, but
Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing. ten23 Health, a contract development and manufacturing organization (CDMO), announced a capacity expansion for the manufacture of sterile drug products
Both companies have a focus on developing and commercializing treatments for rare diseases with a strong focus on patients and supporting communities with little to no existing therapeutic options. Zevra Therapeutics and Acer Therapeutics announced on Aug. 31, 2023, that they have entered a definitive agreement where Zevra would acquire
Novo Nordisk receives the full rights to develop and commercialize the lead program. On Aug. 28, 2023, Embark Laboratories announced it has been acquired by Novo Nordisk, including its lead metabolic program, in addition to entering a three-year research and development collaboration to discover and develop novel pharmaceuticals to treat
Many promising trials in the pipeline may bring big news for major therapeutic areas. Clinical trials are essential for establishing the efficacy of new drugs, observing patients’ reactions to treatments, and representing populations of people that may not always be discussed in everyday conversation. Although many diseases and disorders are
Bristol Myers Squibb has joined Cellares’ Technology Adoption Partnership program just as Cellares launches operations as an integrated development and manufacturing organization. On Aug. 28, 2023, US-based Cellares, an integrated development and manufacturing organization (IDMO), announced that Bristol Myers Squibb has joined its Technology Adoption Partnership (TAP) program, a program
Sandoz, a division of Novartis, announced positive results from the MYLIGHT (NCT04864834) Phase III study, a confirmatory efficacy and safety study for its biosimilar aflibercept. The company, based in Basel, Switzerland, shared the outcomes on Monday. Sandoz is expected to file for regulatory approval for biosimilar aflibercept in the EU
Regeneron Pharmaceuticals Inc. announced that the FDA has approved aflibercept injection 8 mg (EYLEA HD) for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). According to the company, the recommended dose for EYLEA HD is 8 mg (0.07 mL